GET DAILY SIGNALSBioHarvest Sciences (BHST): Analyst Targets Suggest +545% Upside, But Execution Remains the Key Question
Key Takeaways
- The central stock price target of $10.50 is the arithmetic mean of four verified analyst price targets, which range from a low of $5 to a high of $15.
- With BioHarvest Sciences shares recently trading near $1.63, reaching $10.50 would require a rise of roughly 545% — a very large move by any measure.
- The four firms covering the stock — H.C. Wainwright ($14), Craig-Hallum ($15), Maxim Group ($5), and Roth MKM ($8) — all rate it Buy, but the wide $5–$15 spread signals sharp disagreement about execution and valuation.
- Bullish support rests on the company's Botanical Synthesis platform, its first CDMO (contract development and manufacturing organization) supply agreement, and a Tate & Lyle sweetener collaboration.
- The biggest risks are persistent net losses and cash burn, diluted revenue guidance for 2026, and a share price that has fallen roughly 76% over the past 52 weeks.
- Analysts' optimistic targets may not have caught up with the stock's sharp decline, which itself is a key reason the implied upside looks so extreme.
- For more detail on the company's Major News, Today's Price Move, Forecast, and Earnings, explore the dedicated ticker pages.
- For automated, AI-driven trade ideas, explore Trending AI Robots.
Analyst Consensus and Price Targets
BioHarvest Sciences Inc. is a Vancouver-based biotechnology company, not an ETF. It uses a patented Botanical Synthesis platform to grow plant-based compounds without cultivating the underlying plant, operating two segments: a Products business led by the VINIA red-grape-cell supplement and a CDMO Services unit. The $10.50 central target is the simple average of four current analyst price targets: H.C. Wainwright's Amit Dayal at $14, Craig-Hallum's Matt Hewitt at $15, Maxim Group's Anthony Vendetti at $5 (cut from $12 in August 2026), and Roth MKM's Sean McGowan at $8 (cut from $10 the same month). I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The low-to-high range of $5 to $15 is exceptionally wide — a threefold gap — reflecting genuine disagreement about how quickly the CDMO pipeline can convert into revenue and whether the company can reach profitability without further dilution. All four firms carry Buy ratings, so there are no Hold or Sell views to offset the bullish tilt. Notably, several targets were trimmed in August 2026 after second-quarter revenue fell short of expectations, while H.C. Wainwright and Craig-Hallum held their higher objectives. This divergence, rather than a single number, is the more useful signal for investors.
Where the Stock Stands Today
BioHarvest Sciences (BHST) recently traded near $1.63, down roughly 7% after its third-quarter 2026 results, and well below its 52-week high of $8.30. Its market capitalization is roughly $40 million. At this level, moving to the $10.50 central target requires an advance of approximately 545%, which must be classified as a very large move rather than a modest or incremental one.
The company is not yet profitable: trailing twelve-month revenue was about $35.5 million against a net loss near $11 million, or negative EPS (earnings per share) of roughly $0.51. Third-quarter revenue of $7.9 million missed consensus by about $1.4 million. Management has also lowered full-year 2026 guidance to $32–$33.5 million in revenue with an adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) loss of $5.5–$7.5 million. A path to $10.50 would therefore depend less on current results and more on the successful commercialization of CDMO contracts that are only expected to contribute meaningfully from 2027.
Drivers That Could Support a Move Higher
The strongest support for the bull case is the company's signed CDMO manufacturing and supply agreement for a rare, high-value plant-based fragrance ingredient, which management estimates could generate $20–$30 million of revenue over 2027–2028, with limited production potentially beginning in the first half of 2027. A separate collaboration with Tate & Lyle on a next-generation sweetener has passed a key development milestone, and the company has advanced its saffron and olive-cell assets. Cash and equivalents of about $12.5 million at September 30, 2026, plus a modest share repurchase program, provide some near-term runway. If even a portion of the CDMO pipeline converts to revenue, the current price-to-sales ratio near one could look inexpensive relative to the growth analysts are modeling.
Key Risks That Could Keep the Target Out of Reach
The principal obstacle is straightforward: BioHarvest continues to burn cash and lose money while its highest-value revenue streams remain prospective. Full-year guidance has been reduced, and the CDMO revenue outlook depends on completing development, achieving production readiness, and executing with partners — all of which carry timing risk. The company has also diluted shareholders, with shares outstanding up roughly 28% year over year. A share price down about 76% over 52 weeks suggests the market is pricing in execution risk that the analyst targets, several of which predate the recent declines, may not fully reflect. Any further fundraising, guidance cuts, or delays to the fragrance program could keep the stock anchored far below the average target.
Technical Picture and Market Structure
The technical picture is bearish. The stock sits near its 52-week low of $1.37, well below its 200-day moving average near $3.10, while the 50-day moving average sits near $1.65. The prior 52-week high of $8.30 and the $5 and $8 analyst targets form logical overhead zones that would need to be reclaimed before $10.50 becomes relevant. For a low-float small-cap with limited institutional ownership, any sustained recovery would likely require a decisive break back above the $3–$4 area, which currently acts as major resistance.
What Investors Should Monitor Next
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms do not always state this explicitly and their assumptions can differ materially. Investors should monitor the fragrance supply agreement's development milestones and any signs of first production revenue, the Tate & Lyle sweetener program, quarterly cash balances and any indication of new financing, and whether management can hold the revised 2026 guidance while improving VINIA customer retention. Full-year 2027 revenue contributions from the CDMO segment, rather than near-term earnings, are the key variable that would bring the central target into view or push it further away.
Using AI Signals for a Dynamic View
For traders seeking a more dynamic view of this volatile name, Tickeron's AI Daily Buy/Sell Signals offer a complementary approach. The system uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. Rather than relying on a single static price target, traders can use these signals to spot changing trends, monitor existing positions, and surface new opportunities more efficiently. Consider pairing fundamental research with these AI-generated signals as part of a broader, disciplined process.
Exploring Tickeron’s AI Tools for Research
In my own work on names like this, I’ve found Tickeron’s AI Trading Bots helpful for testing scenario-based strategies and seeing how automated systems might respond to shifts in the CDMO pipeline or guidance updates. The platform lets users review historical performance and risk parameters in a straightforward way, which can add context when weighing the wide analyst range against the company’s current execution challenges. It’s one more lens I sometimes apply alongside traditional research before forming a view on volatile small-caps.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BHST in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 04, 2026
BHST may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 42 of 47 cases where BHST's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 62 cases where BHST's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on BHST as a result. In 113 of 138 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for BHST just turned positive on November 10, 2026. Looking at past instances where BHST's MACD turned positive, the stock continued to rise in 41 of 49 cases over the following month. The odds of a continued upward trend are 84%.
BHST moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +12.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where BHST advanced for three days, in 165 of 208 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Aroon Indicator entered an Uptrend today. In 91 of 109 cases where BHST Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.
Bearish Trend Analysis
The 10-day RSI Indicator for BHST moved out of overbought territory on October 14, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 17 similar instances where the indicator moved out of overbought territory. In 15 of the 17 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.
The 10-day moving average for BHST crossed bearishly below the 50-day moving average on October 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BHST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.663) is normal, around the industry mean (6.914). P/E Ratio (0.000) is within average values for comparable stocks, (7.137). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (8.458). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (0.992) is also within normal values, averaging (5.003).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. BHST’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 89 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BHST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry FoodMajorDiversified
Advertisement